A CRISPR-based gene-editing therapy could be a one-and-done treatment for high cholesterol and high triglycerides, a study suggests.

MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to early-stage data presented Friday at the annual…

Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to a new research update.